PMID: 2113592May 1, 1990Paper

The effect of recombinant interleukin 2 in combination with mitomycin C on advanced cancer

The Japanese Journal of Surgery
T AkiyoshiH Matsuoka

Abstract

We recently discovered that the ability of cancer patients to generate lymphokine-activated killer (LAK) cells became remarkably augmented after mitomycin C (MMC) administration. Based on our clinical findings, we designed a treatment regimen comprised of MMC 12 mg/m2 given intravenously on day 1 and recombinant interleukin 2 (rIL 2) 700 U/m2 given intravenously every 12 hr from day 4 through day 8, when the generation of LAK cells had been shown to be markedly increased. Ten patients with various advanced carcinomas for which standard therapy had failed or no standard therapy was available, were treated with this regimen. Of these ten, three had a partial response and three others had a minor response. Fevers were common and anemia occurred in four patients, but nevertheless, severe toxicity was not encountered. These results indicated that rIL 2 in combination with MMC might be effective against advanced carcinoma without causing severe toxicity when these drugs are used in an appropriate combination.

References

Sep 1, 1976·Cancer Treatment Reviews·S T Crooke, W T Bradner
Jan 1, 1987·Cancer Immunology, Immunotherapy : CII·T AkiyoshiH Tsuji
Apr 9, 1987·The New England Journal of Medicine·W H WestR K Oldham
Jan 1, 1985·Cancer Immunology, Immunotherapy : CII·H ShindoS Kishimoto
Jan 1, 1982·Cancer Immunology, Immunotherapy : CII·T OguraY Yamamura
Nov 30, 1982·Biochemical and Biophysical Research Communications·S HinumaK Tsukamoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.